Storage of Platelets in Additive Solutions: Effects of Phosphate

Gulliksson, H.; Larsson, Stella; Kumlien, Gunilla; Shanwell, Agneta

doi:10.1046/j.1423-0410.2000.7830176.x

Cited by 71 publications

(73 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results show that PLTs stored in citrate‐free PAS‐III maintain a pH level of at least 7.0 throughout a 7‐day storage period. These data suggest the buffering capacity provided by the phosphate in citrate‐free PAS‐III may preserve cell viability better than an additive solution lacking phosphate . A recent study has suggested that unbuffered saline strikingly impairs PLT function in vitro, highlighting the importance of pH and cell quality .…”

Section: Discussionmentioning

confidence: 91%

Sodium citrate contributes to the platelet storage lesion

2019

View full text Add to dashboard Cite

BACKGROUND: Sodium citrate has become the preferred anticoagulant used for apheresis collection and has been included in commercial platelet additive solutions (PASs) since PAS-II. It was suggested that citrate be included in PASs to prevent spontaneous aggregation. Reports in cell lines and cord blood have demonstrated that concentrations of citrate present in PAS formulations (10 mM) cause apoptosis. We evaluated whether the removal of citrate from PAS-III could improve platelet storage. STUDY DESIGN AND METHODS: Study 1 evaluatedthe effects of a citrate dose response on the storage of platelets in 65% PAS containing sodium chloride, sodium acetate, and phosphate. Study 2 compared the cell quality and function of platelets stored in 65% citrate-free PAS-III or PAS-III containing 10 mM of citrate. Measurements included cell count, blood gases, flow cytometry analysis of surface activation markers, and aggregation. RESULTS: Study 1 identified that inclusion of citrate in PAS resulted in a dose-dependent increase in glucose utilization, lactate formation, P-selectin expression, phosphatidylserine (PS) exposure, and reactive oxygen species (ROS) formation. Study 2 showed similar results in which platelets stored in citrate-free PAS-III benefited through better maintenance of glucose utilization with less lactate production, P-selectin expression, PS exposure, and ROS formation compared to citratecontaining PAS-III. Platelets stored in citrate-free PAS-III had aggregation responses that were at least 10% greater than those platelets stored in PAS-III. CONCLUSION: Storage of apheresis platelets incitrate-free PAS-III improved multiple storage parameters including glucose utilization, lactate production, Pselection expression, PS exposure, and ROS formation and resulted in a modest increase in aggregation.ABBREVIATIONS: ACD = anticoagulant citrate dextrose solution; ADP = adenosine diphosphate; CPD = citrate-phosphate-dextrose; PASs = platelet additive solutions; PS = phosphatidylserine; ROS = reactive oxygen species; TRAP6 = thrombin receptor activator peptide 6.* Significantly different than Day 5, 0 mM citrate bicarbonate levels; one-way analysis of variance, p = 0.029. † Significantly different than Day 5, 0 mM citrate bicarbonate levels; one-way analysis of variance, p = 0.003.

show abstract

Section: Discussionmentioning

confidence: 91%

Sodium citrate contributes to the platelet storage lesion

2019

View full text Add to dashboard Cite

show abstract

“…After 1 June, 1998, ''split'' apheresis single donor platelets were prepared using a different blood cell separator (Cobe Spectra; Cobe Lakewood, CO) with an integrated leukoreduction system. After separation, platelets were suspended in plasma and platelet additive solution (10).…”

Section: Discussionmentioning

confidence: 99%

Leukocyte Depleted, Unscreened Blood Products Give a Low Risk for CMV Infection and Disease in CMV Seronegative Allogeneic Stem Cell Transplant Recipients with Seronegative Stem Cell Donors

Ljungman¹,

Larsson²,

Kumlien³

et al. 2002

Scandinavian Journal of Infectious Diseases

View full text Add to dashboard Cite

Leukocyte depletion (LD) by blood product filtration has been shown to be similarly effective to the use of screened, CMV seronegative blood products to prevent CMV disease in CMV seronegative allogeneic stem cell transplant (SCT) patients with CMV seronegative donors. The aim of this retrospective study was to determine the risk for development of CMV infection requiring preemptive therapy and for CMV disease if unscreened products treated by prestorage LD is used. Forty-nine consecutive patients transplanted after June 1995 were included. As a control group, 33 patients transplanted from January 1992 to June 1995 in whom a combination of CMV seronegative and LD blood products were given. All patients were monitored weekly by a leukocyte-based PCR for CMV DNA detection. Preemptive therapy was initiated after two consecutively positive tests. No patient developed CMV disease in either group. CMV DNA was detected in 6/49 (p = NS) in the study group and in 3/33 patients in the historical control group. Two patients in the study group were given preemptive therapy compared to one patient in the control group. This study suggests that the risk for CMV disease and the need for preemptive therapy against CMV is low in CMV seronegative allogeneic SCT patients receiving grafts from CMV seronegative stem cell donors receiving LD blood products. Thus, this strategy can be safely used together with PCR monitoring and preemptive therapy.

show abstract

“…The pools were mixed with 300 mL of PLT storage solution (SSP + , MacoPharma, Tourcoing, France), which is identical to PAS-IIIM. 24 The suspension was centrifuged at 527 ¥ g for 7.5 minutes. The PCs were isolated using the same BagPress as before.…”

Section: Preparation Of Pcsmentioning

confidence: 99%